Medtronic office at 6700 Shingle Creek Parkway in Brooklyn Center, Minnesota. Credit: Tony Webster / Flickr (Creative Commons).

Medtronic has enrolled the first participant in the Expand URO US clinical trial of the Hugo robotic-assisted surgery (RAS) system.

Dr Michael Abern has performed the robotic-assisted prostatectomy procedure at Duke University Hospital in Durham, North Carolina.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The single-arm, prospective, multi-centre Expand URO trial will assess the performance and safety of the Hugo RAS system for urologic procedures.

The Hugo RAS system has been designed to reduce the ownership total cost and optimise system utilisation.

It is a modular and portable platform that can be moved between ORs and configure to fit both patient and procedure.

In the study, Hugo RAS system is intended to be utilised for urologic surgical procedures that include radical cystectomy, nephrectomy (partial or radical), and radical prostatectomy procedures at sites in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Expand URO clinical trial will enrol 122 patients at six sites in the country.

The company stated that the study is being conducted according to an Investigational Device Exemption received from the US Food and Drug Administration (FDA).

Medtronic Medical Surgical Portfolio Surgical Robotics business chief medical officer Carla Peron said: “Scientific evidence is the bedrock of healthcare technology innovation and adoption. It creates and builds trust among clinicians and patients.

“We’re proud to further that important pursuit with the Hugo RAS system in partnership with hospitals and surgical teams in the United States who share our commitment to patients.”

Combined with Touch Surgery Enterprise, the Hugo RAS system provides a smart, digitally enabled surgical experience.

Hugo is currently being used in various procedures in gynaecology, urology, and general surgery at hospitals across three continents, outside the US.

It received CE mark approval for use in urological and gynaecological procedures in October last year.